{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:20:04Z","timestamp":1789010404751,"version":"build-2803163510"},"reference-count":207,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite rapid advances in treatment approaches of multiple myeloma (MM) over the last two decades via proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs), their efficacies are limited. MM still remains incurable, and the majority of patients shortly relapse and eventually become refractory to existing therapies due to the genetic heterogeneity and clonal evolution. Therefore, the development of novel therapeutic strategies with different mechanisms of action represents an unmet need to achieve a deep and highly durable response as well as to improve patient outcomes. The antibody-drug conjugate (ADC), belanatmab mafadotin, which targets B cell membrane antigen (BCMA) on plasma cells, was approved for the treatment of MM in 2020. To date, numerous immunotherapies, including bispecific antibodies, such as bispecific T cell engager (BiTE), the duobody adoptive cellular therapy using a dendritic cell (DC) vaccine, autologous chimeric antigen (CAR)-T cells, allogeneic CAR-natural killer (NK) cells, and checkpoint inhibitors have been developed for the treatment of MM, and a variety of clinical trials are currently underway or are expected to be planned. In the future, the efficacy of combination approaches, as well as allogenic CAR-T or NK cell therapy, will be examined, and promising results may alter the treatment paradigm of MM. This is a comprehensive review with an update on the most recent clinical and preclinical advances with a focus on results from clinical trials in progress with BCMA-targeted immunotherapies and the development of other novel targets in MM. Future perspectives will also be discussed.<\/jats:p>","DOI":"10.3390\/cancers13112712","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T03:45:29Z","timestamp":1622432729000},"page":"2712","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Hiroko","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Pathology, Keio University, School of Medicine, Tokyo 160-8582, Japan"},{"name":"Division of Hematology, Department of Internal of Medicine, Keio University, School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"e534","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajikumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristic","volume":"133","author":"Charlotte","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy implications for treatment decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed or refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune-based therapies in the management of multiple myeloma","volume":"10","author":"Zabwar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.15116","article-title":"Investigational agents in immunotherapy: A new horizon for the treatment of multiple myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in hematologic malignancies: Past, present, and future","volume":"10","author":"Im","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2011.08790.x","article-title":"Monoclonal antibodies in the treatment of multiple myeloma","volume":"154","author":"Richardosn","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Fonseca","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): Interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomized, open-label, phase 3 trial","volume":"14","author":"Weisel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2017.258","article-title":"Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial","volume":"32","author":"Ailawadhi","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, Bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory Drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-319-91439-8_8","article-title":"Pomalidomide","volume":"212","author":"Engelhardt","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/1078-0432.CCR-14-3190","article-title":"CD38-targeted immunochemotherapy in refractory multiple myeloma: A new horizon","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc gamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratmumab monotherapy in patients with treatment-refratcory multiple myeloma (SIRIUS): An open-label, randomized, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory myeloma","volume":"130","author":"Chari","year":"2018","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","article-title":"Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk","volume":"13","author":"Weisel","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38 targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamesasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed \/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomized, multicenter, open-label, phase 3 study","volume":"294","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Barou","year":"2008","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma. A review of target, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Grafall","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.1148.1148","article-title":"First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibocy-drug conjugate, GSK2857916, in relapsed\/refractoy multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomized, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamusutine versus bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: Primary results of the GADOLIN study","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin physician\u2019s choice in CD30 positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomizse, phase 3, multicenter trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+PTCL","volume":"26","author":"Barta","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma: Final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarijian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogmaicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_67","first-page":"230","article-title":"Salvage chemoimminotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia a phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow up from the randomised phase 3 INO-VATE study","volume":"125","author":"Kantarijian","year":"2019","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1078155211412842","article-title":"Immune alteration in untreated and treated multiple myeloma","volume":"18","author":"Dasanu","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.blre.2013.04.004","article-title":"Regulating the regulators in cancer immunosuppression in multiple myeloma (MM)","volume":"27","author":"Feyler","year":"2013","journal-title":"Blood Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and predonisone or untreated myeloma","volume":"378","author":"Maeteos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and predonisone in newly diagnosed multiple myeloma (ALCYONE): A randomized, open-label, phase 3 trial","volume":"395","author":"Maeteos","year":"2020","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intraveneous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicenter, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lunes of therapy (PLEIADES): An open-label phase II study","volume":"192","author":"Chari","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2020-135874","article-title":"APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexameyhasone (D-Pd) versus pomalidomide anddexamethasone (Pd) alone in patients (Pts) with relapsed or refractory multiple multiple myeloma (RRMM)","volume":"136","author":"Dimopoulos","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/jbmr.2277","article-title":"Blockade or CD26 signaling inhibits human osteoclast development","volume":"29","author":"Nishida","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_83","first-page":"1","article-title":"CD26 is a potential therapeutic target by humanized anti-body for the treatment of multiple myeloma","volume":"9","author":"Nishida","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2016","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE (bisecific T-cell engager) molecule in relapsed\/refractory multiple myeloma","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by cotrolled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a nobvel BCMA \u00d7 CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_92","first-page":"180","article-title":"Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma","volume":"136","author":"Grafall","year":"2020","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA \u00d7 CD3 bispecific monoclonal angtibocy induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2020-139893","article-title":"Initial results of a phase I study of TNB-383B, a BCMA \u00d7 CD3 bispecific T-cell redirecting antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D \u00d7 CD3 antibody to treat multiple myeloma","volume":"134","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2020-133873","article-title":"A phase 1, first-in-human study of Talquetamab, a G protein-coupled receptor family C group 5 member (GPRC5D) \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2020-136985","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody in relapsed\/refractory multiple myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA)2+1 T cell engager (TCE) CC-93269 in patients with relapsed\/refractory myeloma","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase 1 study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Raje","year":"2019","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"TPS3132","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132","article-title":"Phase 1, multicenter open-label study of single-agent bispecific antibody t-cell engager GBR1342 in relapsed\/refractory multiple myeloma","volume":"36","author":"Richter","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG424, 1 novel anti-CD38\/CD3 bispecific T-cell recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Fajardo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_102","first-page":"2115","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Ahao","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed or refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"A phase 1 study of anti-BCMA antibody-drug conjugate AMG224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2020","journal-title":"Leukemia"},{"key":"ref_105","unstructured":"(2021, March 01). A Study of CC-99712, A BCMA Antibody-Drug-Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma. ClinicalTrials. Gov Identifier: NCT04036461 (26 August 2019~27 May 2025), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04036461."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V128.22.4486.4486","article-title":"Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: Clinical activity in patients with relapsed and\/or refractory multiple myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-016-0380-0","article-title":"Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: Pre-clinical studies","volume":"10","author":"Schonfeld","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase 1 study to assess the safety and pharmacokinetics of single-agent lorotuzumab mertansine (IMGN901) in patients with relapsed\/refractory CD56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2741\/4202","article-title":"Lorvotuzumab mertansine: Antibody-drug-conjugate for CD56+ multiple myeloma","volume":"19","author":"Berdeja","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/1535-7163.MCT-12-1170","article-title":"Milatuzumab-SN-38 conjugates for the treatment of CD74 cancer","volume":"6","author":"Govindan","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I multicenter, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","author":"Kaufman","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_112","first-page":"147","article-title":"Engineering strategies to overcome the current road blocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Holstein, S.A., and Lunning, M.A. (2019). CAR T-cell therapy in hematologic malignancies: A voyage in progress. Clin. Pharmacol. Therapeut.","DOI":"10.1002\/cpt.1674"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults in B-cell acute lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphoma","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti- BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory myeloma","volume":"4","author":"Grafall","year":"2018","journal-title":"JCI Insight"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Explaratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR-T cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11940-019-0585-y","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: Mechanism, clinical presentation and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr. Treat. Opin. Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpant."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR-T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphoma","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Drent, E., Poels, R., Mulders, M.J., van de Donk, N.W.C.J., Themeli, M., Lokhorst, H.M., and Mutis, T. (2018). Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197349"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J. Cell Immunother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modofication of T cells redirected toward CS1 engages eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"Hudecek, M\/ SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1538-7445.AM2012-3499","article-title":"CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma","volume":"72","author":"Benjiamin","year":"2012","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for immunotherapy of CD70-positive malignancies","volume":"117","author":"Schaffer","year":"2011","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1038\/bcj.2015.3","article-title":"B-cell activating factor in the pathophysiology of multiple myeloma: A target for therapy?","volume":"5","author":"Hengeveld","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated confirmation of integrin \u03b27 is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2020-134324","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: Updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase 1 CRB-402 study of anti-BCMA CAR-T cell therapy bb2127 in patients with relapsed and refractory multiple myeloma: Correction and expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-Bcma CRA-T cell (CT53) in relapsed \/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2020-139802","article-title":"Results from Lummicar-2: A phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and \/or refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2020-142695","article-title":"Phase1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)(PRIM) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long term follow up of a phase 1 first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2020-138734","article-title":"An anti-Bcma CAR-T cell therapy (C-CAR088) shows promising safety and efficacy profile in relapsed or refractory multiple myeloma","volume":"136","author":"An","year":"2020","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2ELOVEbstudy","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of aquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanized anti-CD19 and anti-BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells target triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2020-138614","article-title":"Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogenic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long terminal repeat CRSPER-CAR-coupled universal T cells mediate anti-potent anti-leukemic effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cells subset for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR-T cell therapy: Full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.beha.2020.101141","article-title":"CAR T and CAR NK cels in multiple myeloma: Expanding the targtes","volume":"33","author":"Shah","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.3389\/fimmu.2019.02001","article-title":"A distinct subset of highly proliferative and lentiviral vector transducible NK cells define a readily engineered subset for adoptive cellular therapy","volume":"10","author":"Bari","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.exphem.2005.07.006","article-title":"Efficient gene transfer into primary human natural killer cells by retroviral transduction","volume":"33","author":"Guven","year":"2005","journal-title":"Exp. Hematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: Techniques and clinical implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/gt.2012.88","article-title":"Understanding lentiviral vector chromatin targeting: Working to reduce insertional mutagenic potential for gene therapy","volume":"20","author":"Papayannakos","year":"2013","journal-title":"Gene Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced Natural killer cells in CD19 positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing fully automated separation improved Ex vivo expansion using IL-21 with autologous feeder cells and generation of anti-CD123 CAR expressing effector cells","volume":"28","author":"Kloss","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1084\/jem.161.6.1464","article-title":"A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu11+ granular lymphocytes with a natural killer sensitive tumor cell, K 562","volume":"161","author":"Phillips","year":"1985","journal-title":"J. Exp. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS-1 specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo anti-tumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.3389\/fimmu.2019.03010","article-title":"Recalling the biological significance of immune checkpoints on NK cells: A chance to overcome LAG3, PD1 and CTCL4 inhibitory pathways by adoptive NK cell transfer?","volume":"10","author":"Lanuza","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPER\/CAS9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2017.01.011","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"111","author":"Jung","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2015.51.1.1","article-title":"Dendritic cell-based cancer immunotherapy against multiple myeloma","volume":"51","author":"Hoang","year":"2015","journal-title":"Chon. Med. J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Jung","year":"2015","journal-title":"J. Immunother."},{"key":"ref_186","first-page":"957","article-title":"Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma","volume":"4","author":"Wen","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1083-8791(00)70027-9","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma","volume":"6","author":"Liso","year":"2000","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1080\/10428190701583975","article-title":"Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma lysate","volume":"48","author":"Lee","year":"2007","journal-title":"Leuk. Lymphoma."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"41538","DOI":"10.18632\/oncotarget.14582","article-title":"A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-11-2776","article-title":"Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma and other plasma cell disorders","volume":"18","author":"Bae","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P","article-title":"The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells","volume":"30","author":"Mellerin","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","article-title":"Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma","volume":"110","author":"Qian","year":"2007","journal-title":"Blood"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2011.08850.x","article-title":"Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders","volume":"155","author":"Bae","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2141.2012.09111.x","article-title":"A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma","volume":"157","author":"Bae","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood-2002-08-2554","article-title":"Survivin is a sharped tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells","volume":"102","author":"Schmidt","year":"2003","journal-title":"Blood"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: Update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Bakan","year":"2010","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/leu.2015.104","article-title":"The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibiters in a phase 1 study","volume":"29","author":"Suen","year":"2015","journal-title":"Leukemia"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Phase2 study Pembrolizumab plus lenalidomide plus dexamethasone versus observation in high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of ransomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-na\u00efve multiple myeloma (KEYNOTE-185) randomized, open-label, phase 3 trial","volume":"6","author":"Usami","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma KEYNOTE-183): A ramdomized, open-label, phase 3 trial","volume":"6","author":"Maetos","year":"2019","journal-title":"Lancet Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2712\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:14Z","timestamp":1760162954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":207,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13112712"],"URL":"https:\/\/doi.org\/10.3390\/cancers13112712","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}